Cargando…

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report

Mostrar otras versiones (1)

Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization due to its favorable side effect profile, high efficacy and genetic barrier to resistance. Despite its very good s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulindwa, Frank, Castelnuovo, Barbara, Brusselaers, Nele, Bollinger, Robert, Yendewa, George, Amutuhaire, Willington, Mukashaka, Claudine, Schwarz, Jean-Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617153/ https://www.ncbi.nlm.nih.gov/pubmed/37904127 http://dx.doi.org/10.1186/s12879-023-08712-z

Ejemplares similares

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
por: Mulindwa, Frank, et al.
Publicado: (2023)

Implementation of longitudinal insulin kinetic studies in busy field settings in Uganda: experience from the “glucose metabolism changes in Ugandan HIV patients on dolutegravir based anti-retroviral therapy” (GLUMED study)
por: Mulindwa, Frank, et al.
Publicado: (2023)

Prevalence of Cardiometabolic Disease Risk Factors in People With HIV Initiating Antiretroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda
por: Amutuhaire, Willington, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis
por: Mulindwa, Frank, et al.
Publicado: (2023)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol
por: Mulindwa, Frank, et al.
Publicado: (2022)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus
por: Hirigo, Agete Tadewos, et al.
Publicado: (2022)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

SUN-187 Dolutegravir Causing Diabetes
por: Kamal, Palwasha, et al.
Publicado: (2019)

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
por: Saborido-Alconchel, Abraham, et al.
Publicado: (2023)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Creation of a long-acting nanoformulated dolutegravir
por: Sillman, Brady, et al.
Publicado: (2018)

The Brazilian experience of implementing the active pharmacovigilance of dolutegravir
por: Batista, Cynthia Julia Braga, et al.
Publicado: (2019)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Modifying dolutegravir to PrEPare for long life
por: Mandarino, Angelo
Publicado: (2022)

Synthesis of Dolutegravir Exploiting Continuous Flow Chemistry
por: Nqeketo, Sinazo, et al.
Publicado: (2023)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
por: Van de Wijer, Lisa, et al.
Publicado: (2021)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

Less Is More: A Narrative Review of Deciding When Surgical Intervention Should Be Withheld
por: Stout, Annabel, et al.
Publicado: (2022)

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
por: Bloomgarden, Zachary
Publicado: (2023)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi, Alessandra, et al.
Publicado: (2013)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
por: Nakaharai, Kazuhiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gmnri1sn8pms6je9tiao1ldqm1